Aehr Test Systems Stock Slides Amid Insider Selling and Analyst Concerns

Aehr Test Systems (NASDAQ: AEHR) shares fell sharply in morning trading, extending a recent bout of selling pressure as investors weigh a combination of a recent analyst downgrade, significant insider stock sales, and broader market weakness.

The stock dropped as much as 7.5% to a low of $92.38 before trading near $93.05, continuing a decline that began in the prior session without any new company-specific press releases to act as a catalyst.

Key Drivers of the Decline

A key overhang on investor sentiment is a Zacks Research downgrade from September 14, which lowered its rating on AEHR from "strong-buy" to "hold." The impact of this rating change has continued to pressure the stock in the weeks since.

Adding to investor concerns is a pattern of insider selling at higher price levels in recent months. According to reports, these sales include:

• CEO Gayn Erickson sold 40,000 shares in August.
• Director Howard T. Slayen sold 20,000 shares.
• EVP Alberto Salamone sold nearly 10,000 shares.

Ad

Market observers have also consistently pointed to the company's elevated valuation and its heavy reliance on a small number of key customers as persistent execution risks.

Broader Market Pressure and Analyst Outlook

The decline is occurring within a challenging macroeconomic environment. A weak session for the broader market, with the NASDAQ Composite down 1.2% and the S&P 500 off 0.6%, has created a difficult backdrop for high-beta semiconductor stocks like Aehr.

The analyst community remains divided on the stock's prospects. While the Zacks downgrade is weighing on the shares, Oppenheimer initiated coverage on September 10 with an "outperform" rating and a $120 price target. This follows a previous "buy" rating from Jefferies, which set a $175 target, highlighting a split in Wall Street sentiment that can leave a stock vulnerable to sharp swings. The stock is now trading significantly below its 52-week high of $147.40.